Leukemia Research
Volume 27, Issue 1 , Pages 57-64, January 2003

Cytotoxic and inhibitory effects of 4,4′-dihydroxy chalcone (RVC-588) on proliferation of human leukemic HL-60 cells

  • Guray Saydam

      Affiliations

    • Department of Hematology, School of Medicine, Ege University, Bornova, Izmir, Turkey
  • ,
  • H.Hakan Aydin

      Affiliations

    • Department of Biochemistry, School of Medicine, Ege University, Bornova, Izmir, Turkey
  • ,
  • Fahri Sahin

      Affiliations

    • Department of Hematology, School of Medicine, Ege University, Bornova, Izmir, Turkey
  • ,
  • Ozlem Kucukoglu

      Affiliations

    • Department of Pharmaceutical Chemistry, School of Pharmacy, Ege University, Bornova, Izmir, Turkey
  • ,
  • Ercin Erciyas

      Affiliations

    • Department of Pharmaceutical Chemistry, School of Pharmacy, Ege University, Bornova, Izmir, Turkey
  • ,
  • Ender Terzioglu

      Affiliations

    • Department of Immunology, School of Medicine, Ege University, Bornova, Izmir, Turkey
  • ,
  • Filiz Buyukkececi

      Affiliations

    • Department of Hematology, School of Medicine, Ege University, Bornova, Izmir, Turkey
  • ,
  • Serdar Bedii Omay

      Affiliations

    • Department of Hematology, School of Medicine, Ege University, Bornova, Izmir, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90-232-374-7321; fax: +90-232-374-7321.

Received 1 August 2001; accepted 19 February 2002.

Abstract 

Chalcones have been identified as interesting compounds with cytotoxic and tumor reducing properties. In the present study, the biological activity of synthetic chalcones on myeloid leukemic cells was investigated. Human myeloid HL-60 leukemia cells were exposed to 1–20μM chemicals for 0–96h. The viability of the cells was measured using trypan blue dye exclusion method. 4,4′-Dihydroxy chalcone (RVC-588) was selected for further experiments to determine characteristics of cytotoxicity among other compounds.

The data show that cell viability decreased after treatment and IC50 value was approximately 2μM for RVC-588. Cell differentiation was analyzed with cytofluorometry by changes in expression of glicoprotein surface markers CD11b/Mac-1, CD11c and CD14 together with morphological analysis. A maximum level of expression changes was determined at 72h but these changes were not statistically significant to show the differentiation of HL-60 cells to mature myeloid and/or monocytoid cells. Apoptotic DNA degradation was evaluated and quantitated using sensitive enzyme-linked immunoabsorbant (ELISA) method. Using this technique, a maximum level of apoptosis 1.2-fold higher than control was observed in cultures exposed for 48h to 2μM RVC-588. The DNA ladder assay was subsequently used to determine DNA breaks qualitatively. After 24h, the cells exposed to 2μM RVC-588 was shown to have cytotoxic-late apoptotic ladder pattern compared to control cells.

These data demonstrate that RVC-588 has a high cytotoxic and antitumor activity in HL-60 cells among other chemicals we synthesized. Although the mechanism by which RVC-588 initiated cell death in these cells is presently not known and apoptotic mechanisms are likely to play less role compared to other chalcone analogues reported previously.

Abbreviations:  4,4′-Dihydroxy chalcone, RVC-588, 5,3′-Dimethylaminomethyl chalcone, CS-MR1, 4-[2-(p-Hydroxybenzoyl) vinyl] phenyl nicotinate, CS-NA1, 4-Hydroxy-3-(dimethyaminomethyl) asetofenone, AF-M1

Keywords:  Chalcones, 4,4′-Dihydroxy chalcone, RVC-588, Cytotoxicity, HL-60 cells

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0145-2126(02)00058-9

Leukemia Research
Volume 27, Issue 1 , Pages 57-64, January 2003